Dr. Perez-Soler on the Future of Lung Cancer Therapies

Roman Perez-Soler, MD
Published: Tuesday, Mar 13, 2012

Roman Perez-Soler, MD, Chairman, Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine of Yeshiva University, discusses the desire to find targeted therapies and new driver mutations for smaller molecular subsets of non-small cell lung cancer (NSCLC).

Genetic subtypes of NSCLC, such as those containing mutations in EGFR and EML4-ALK, have been uncovered and successfully targeted. However, important groups still require the concentration of researchers. Areas of potential focus include tumors that contain identifiable alterations but do not have associated targeted pharmaceuticals, subtypes without an identifiable driver mutation, and multiple aberrations implicated in a single tumor.

Perez-Soler labels the mutations currently being targeted as low-hanging fruit and the beginnings of a complex journey to a more desirable location. This journey will require research into complex strategies and new tumor pathways that focus on reaching a more desirable overall prognosis.

A cure for patients with advanced NSCLC may not be possible, notes Perez-Soler. A more plausible goal and approach for future inquiries may be to convert the disease into a manageable chronic disorder.

Roman Perez-Soler, MD, Chairman, Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine of Yeshiva University, discusses the desire to find targeted therapies and new driver mutations for smaller molecular subsets of non-small cell lung cancer (NSCLC).

Genetic subtypes of NSCLC, such as those containing mutations in EGFR and EML4-ALK, have been uncovered and successfully targeted. However, important groups still require the concentration of researchers. Areas of potential focus include tumors that contain identifiable alterations but do not have associated targeted pharmaceuticals, subtypes without an identifiable driver mutation, and multiple aberrations implicated in a single tumor.

Perez-Soler labels the mutations currently being targeted as low-hanging fruit and the beginnings of a complex journey to a more desirable location. This journey will require research into complex strategies and new tumor pathways that focus on reaching a more desirable overall prognosis.

A cure for patients with advanced NSCLC may not be possible, notes Perez-Soler. A more plausible goal and approach for future inquiries may be to convert the disease into a manageable chronic disorder.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x